LetiziaGianni

Associate

Washington + 1.202.879.3484

Connect:

Share

Letizia Gianni has more than eight years of experience in competition law, including governmental roles in Italy and Brussels. Specifically, Letizia served with the DG Competition of the European Commission in Brussels and worked as a special legal advisor to the Italian Ministry of Foreign Affairs.

Letizia's practice focuses on merger control, government investigations, cartels, and antitrust compliance. Prior to joining Jones Day in 2023, Letizia handled a number of high-profile cases with the European Commission and in private practice spanning a variety of industrial sectors such as transportation, energy, pharma, medical devices, chemicals, consumer goods, telecoms, and media.

She is member of the American Bar Association (Antitrust Section).

Experience

  • The Aaron's Company agrees to be acquired by IQVenturesJones Day advised The Aaron's Company, Inc. in the acquisition and take private of Aaron’s by IQVentures Holdings, LLC, a leading fintech organization, for $10.10 per share in cash, or an enterprise value of approximately $504 million.
  • STERIS sells dental segment to an affiliate of Peak Rock CapitalJones Day advised STERIS Plc in the $787.5 million sale of Dental segment to Peak Rock Capital, a leading middle-market private investment firm.
  • TopBuild attempts to acquire Specialty Products & InsulationJones Day advised TopBuild Corp. (NSYE: BLD) in its attempted acquisition of Specialty Products & Insulation from private equity firm Incline Equity Partners in an all-cash transaction valued at $960 million.
  • Autodesk acquires PIX business of X2XJones Day acted as antitrust counsel to Autodesk, Inc. in the acquisition of the PIX business of X2X.
  • ETS acquires PSIJones Day advised Educational Testing Service (ETS) in its acquisition of PSI Services LLC, a global leader in test development and delivery across workforce certification and licensure.
  • Signature Aviation acquires MeridianJones Day advised Signature Aviation in the acquisition of Meridian, an award-winning private aviation company with bases in Teterboro, NJ (TEB) and Hayward, CA (HWD).
  • Eastman Chemical Company sells Texas City operations to INEOS Acetyls for $490 millionJones Day advised Eastman Chemical Company (NYSE: EMN) on the sale of its Texas City operations to INEOS Acetyls, a global manufacturer and supplier of acetic acid and related chemicals owned by the INEOS Group for approximately $490 million.
  • HanesBrands Appoints Three New Independent DirectorsJones Day is advising Hanesbrands, an American multinational clothing company, on activism triggered by public letter from activist shareholder Barington Capital, including the potential disposition of the Champion business. Hanesbrands recently announced its settlement with Barington, involving the appointment of three new independent directors and a consulting agreement between the company and Barington.
  • Timken acquires Des-CaseJones Day advised The Timken Company in the acquisition of Des-Case Corp., a Nashville, Tenn.-based manufacturer of specialty filtration products for industrial lubricants.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
    • View All

    July/August 2023 External Publications

    Competition and Financial Stability: The Emerging Regulatory Framework for Bank Merger Reviews, The M&A Lawyer, Vol. 27, Issue 7

    Additional Publications

    • August 22, 2023
      Competition and Financial Stability: The Emerging Regulatory Framework for Bank Merger Reviews, The M&A Lawyer

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.